ERBB2 and breast carcinoma: On the other hand, for patients with node-negative small HER2+ breast cancers <3 cm, the APT trial demonstrated that a regimen of single-agent adjuvant paclitaxel with trastuzumab (TH) confers a very low risk of recurrence with a favorable profile of side effects15.